This Month in Gastroenterology Jan Tack, John M. Carethers  Gastroenterology  Volume 136, Issue 2, Pages 369-372 (February 2009) DOI: 10.1053/j.gastro.2008.12.041 Copyright © 2009 Terms and Conditions

Figure 1 Percentage of patients in remission versus recurrence 1 year after intestinal resection for Crohn's disease by random assignment to infliximab or placebo. Gastroenterology 2009 136, 369-372DOI: (10.1053/j.gastro.2008.12.041) Copyright © 2009 Terms and Conditions

Figure 2 Outcomes of therapy and occurrence of viral resistance during treatment with lamivudine and telbivudine in chronic hepatitis B patients who are HBeAG positive or HBeAG negative. Gastroenterology 2009 136, 369-372DOI: (10.1053/j.gastro.2008.12.041) Copyright © 2009 Terms and Conditions

Figure 3 Hepatitis C viral responses to the combination therapy of peginterferon alfa-2a and ribavirin. Intention-to-treat (ITT): analysis of patients receiving ≥1 dose of study treatment, including withdrawals; withdrawn cases without HCV RNA testing at 24 weeks posttreatment are counted as treatment failure. Per protocol (PP): analysis of patients completing ≥12 weeks of treatment. B+C, HBsAg-positive patients with chronic hepatitis C; C, HBsAg-negative patients with chronic hepatitis C; VR, virologic response (HCV RNA clearance at the end of treatment); SVR, sustained virologic response (HCV RNA clearance at 24 weeks posttreatment). Gastroenterology 2009 136, 369-372DOI: (10.1053/j.gastro.2008.12.041) Copyright © 2009 Terms and Conditions

Figure 4 ILZ-TG (transgenic) mice are less susceptible than WT mice to DNBS-induced colitis. Four and 7 days after DNBS administration, mice were killed and body weight (A) and macroscopic damage score (B) evaluated. Bars are the means ± SE of 10 mice for each group. *P < .01 DNBS versus vehicle; oP < .01 DNBS-treated GILZ-TG versus DNBS-treated WT. Gastroenterology 2009 136, 369-372DOI: (10.1053/j.gastro.2008.12.041) Copyright © 2009 Terms and Conditions